This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20 monoclonal antibody treatment in clinical practice. The index date was defined as the date of anti-CD20 drug initiation during the study period. The baseline period was defined as 12 months prior to the index date.
Study Type
OBSERVATIONAL
Enrollment
326
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Percentage Change per Year in Immunoglobulin G (IgG) Levels in Patients Receiving Ocrelizumab
Time frame: Up to 5 years
Percentage of Patients Newly Treated with Ocrelizumab With Low Immunoglobulin Values
Low immunoglobulin values were defined as greater than or equal to 1 immunoglobulin G (IgG) lab value of less than 500 milligrams per deciliter (mg/dL) or greater than or equal to 1 immunoglobulin M (IgM) lab value of less than 25 mg/dL.
Time frame: Up to 5 years
Percentage Change per Year in Immunoglobulin M (IgM) Levels in Patients Receiving Ocrelizumab
Time frame: Up to 5 years
Percentage Change per Year in IgG Levels Associated With Risk Factors in Patients Treated With Ocrelizumab
Risk factors included: age and disease duration.
Time frame: Up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.